TY - JOUR
T1 - Selective inhibition of arachidonic acid metabolite release from human lung tissue by antiinflammatory steroids
AU - Schleimer, R. P.
AU - Davidson, D. A.
AU - Lichtenstein, L. M.
AU - Adkinson, N. F.
PY - 1986
Y1 - 1986
N2 - The effects of antiinflammatory steroids on arachidonic acid metabolite release from human lung fragments were analyzed. Incubation of lung fragments for 24 h with 10-6 M dexamethasone inhibited the net release of the prostacyclin metabolite 6-keto-PGF(1α), PGE2, and PGF(2α) from lung fragments stimulated with anti-IgE but failed to inhibit the anti-IgE-induced release of PGD2, TXB2, and iLTC4. The IC50 of dexamethasone for inhibition of both spontaneous and anti-IgE-induced 6-keto-PGF(1α) release was approximately 2 x 10-8 M, and a 6-hr preincubation with the drug was required for 50% inhibition of prostaglandin release. Other agents were tested for activity in stimulating arachidonic acid metabolite release from human lung fragments. FMLP (fmet-leu-phe) stimulated the release of all metabolites tested (6-keto-PGF(1α), PGD2, PGE2, PGF(2α), TXB2, iLTC4); platelet-activating factor (PAF), but not lysoPAF, stimulated the release of PGD2, TXB2, and iLTC4. In contrast to the case with anti-IgE, where dexamethasone failed to inhibit net PGD2 and TXB2 release, the steroid inhibited the release of these metabolites stimulated by both FMLP and PAF. The steroid inhibited iLTC4 release induced by the highest concentration of PAF (10-6 M) but did not inhibit iLTC4 release stimulated by either 10-7 M PAF, FMLP, or anti-IgE. Because neither FMLP nor PAF caused the release of PGD2 or TXB2 from purified human lung mast cells, and because they also failed to induce histamine release from lung fragments, it is suggested that these stimuli produce PGD2 and TXB2 release in lung fragments through an action on a cell distinct from the mast cell. This suggestion is supported by the selective inhibition of the release of these arachidonic acid metabolites by dexamethasone. We suggest that the inhibitory action of steroids on arachidonic acid metabolite in human lung fragments contributes to their therapeutic efficacy in pulmonary diseases.
AB - The effects of antiinflammatory steroids on arachidonic acid metabolite release from human lung fragments were analyzed. Incubation of lung fragments for 24 h with 10-6 M dexamethasone inhibited the net release of the prostacyclin metabolite 6-keto-PGF(1α), PGE2, and PGF(2α) from lung fragments stimulated with anti-IgE but failed to inhibit the anti-IgE-induced release of PGD2, TXB2, and iLTC4. The IC50 of dexamethasone for inhibition of both spontaneous and anti-IgE-induced 6-keto-PGF(1α) release was approximately 2 x 10-8 M, and a 6-hr preincubation with the drug was required for 50% inhibition of prostaglandin release. Other agents were tested for activity in stimulating arachidonic acid metabolite release from human lung fragments. FMLP (fmet-leu-phe) stimulated the release of all metabolites tested (6-keto-PGF(1α), PGD2, PGE2, PGF(2α), TXB2, iLTC4); platelet-activating factor (PAF), but not lysoPAF, stimulated the release of PGD2, TXB2, and iLTC4. In contrast to the case with anti-IgE, where dexamethasone failed to inhibit net PGD2 and TXB2 release, the steroid inhibited the release of these metabolites stimulated by both FMLP and PAF. The steroid inhibited iLTC4 release induced by the highest concentration of PAF (10-6 M) but did not inhibit iLTC4 release stimulated by either 10-7 M PAF, FMLP, or anti-IgE. Because neither FMLP nor PAF caused the release of PGD2 or TXB2 from purified human lung mast cells, and because they also failed to induce histamine release from lung fragments, it is suggested that these stimuli produce PGD2 and TXB2 release in lung fragments through an action on a cell distinct from the mast cell. This suggestion is supported by the selective inhibition of the release of these arachidonic acid metabolites by dexamethasone. We suggest that the inhibitory action of steroids on arachidonic acid metabolite in human lung fragments contributes to their therapeutic efficacy in pulmonary diseases.
UR - http://www.scopus.com/inward/record.url?scp=0022626769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022626769&partnerID=8YFLogxK
M3 - Article
C2 - 3082976
AN - SCOPUS:0022626769
SN - 0022-1767
VL - 136
SP - 3006
EP - 3012
JO - Journal of Immunology
JF - Journal of Immunology
IS - 8
ER -
